In a recent interview with Pharmacy Times, Lee Greenberger, PhD, chief scientific officer of the Leukemia and Lymphoma Society, said the development of chimeric antigen receptor (CAR) T-cell therapies is a major step for the treatment of some cancers.
Pharmacy Times® interviewed Chad Landmon, JD, chair of intellectual property and FDA practice groups at Axinn, Veltrop & Harkrider, on the FDA’s EUA process for COVID-19 vaccines.
Paul Ament, PharmD, reviews the data from studies looking into the prevention of VTEs and Riley Bowers, PharmD, shares the real-world data to the studies.
A panel of experts discuss the risks vs benefits of prophylactic care for patients to prevent VTE.
Paul Ament, PharmD, reviews the data from studies looking into the prevention of VTEs and Riley Bowers, PharmD, shares the real-world data to the studies.
Pharmacy Times® interviewed Sarah Browne, MD, senior director of vaccine development at Altimmune, on the commencement of a phase 1 clinical trial of a single-dose, intranasal COVID-19 vaccine.
In a recent interview with Pharmacy Times, Council Powell, PharmD, region director with CVS, said pharmacists and technicians are hard at work administering COVID-19 vaccines around the country.
Pharmacy Times® interviewed Farah Towfic, PharmD, MBA, the director and CEO of operations at US Pharmacopeia, on the FDA’s approval of the Pfizer and BioNTech COVID-19 vaccine’s updated cold storage requirements.
Paul Ament, PharmD, reviews the guidelines for the treatment of VTE.
Amesh Adalja, MD, FIDSA, FACP, FACEP, discussed the distribution prospects for the Johnson & Johnson COVID-19 vaccine in light of it being possible to store it at standard refrigeration temperatures for up to 3 months.
Amesh Adalja, MD, FIDSA, FACP, FACEP, a senior scholar at the Johns Hopkins Center for Health Security, discusses how Johnson & Johnson’s COVID-19 vaccine provides effective support in prevention of severe disease and hospitalization.
Pharmacy Times® interviewed Amesh Adalja, MD, FIDSA, FACP, FACEP, a senior scholar at the Johns Hopkins Center for Health Security, on how the proposed EUA for Johnson & Johnson’s single-dose vaccine may impact the COVID-19 vaccine distribution and administration process.
Pharmacy Times® interviewed Kenneth Thorpe, PhD, the former deputy assistant secretary at the HHS during the Clinton administration, on how pandemic preparedness lessons from COVID-19 may help to tackle the antimicrobial resistance health crisis.
Pharmacy Times® interviewed David Silverstein, JD, MS, a partner in Axinn’s Intellectual Property and FDA practice groups, on what may be coming to market in the rapidly growing cell therapy space, and the role pharmacists may play in this emerging landscape.
Pharmacy Times® interviewed J. David Robertson, PhD, director of University of Missouri Research Reactor, on a new collaboration with Advanced Accelerator Applications International to develop a targeted therapy for certain types of cancerous tumors.
Crystal Lewis, a third-year pharmacy student at Washington State University, about her top 3 study snacks for pharmacy students.
Pharmacy Times® interviewed Kurt Proctor, PhD, RPh, senior vice president of strategic initiatives at the NCPA, on his outlook on the future of the COVID-19 vaccination rollout under the Biden administration.
Pharmacy Times® interviewed Susan Swindells, MD, of the University of Nebraska Medical Center, on the impact of the recently FDA-approved once-monthly, long-acting HIV regimen on how providers care for patients with the virus.
Pharmacy Times® interviewed Kurt Proctor, PhD, RPh, senior vice president of strategic initiatives at the NCPA, on how the Biden administration’s launch of the Federal Retail Pharmacy Program may affect the COVID-19 vaccination rollout.
Pharmacy Times® interviewed Kim White, MBA, vice president of Numerof & Associates, on how changes in business strategies in hospitals due to the COVID-19 pandemic may affect how hospital pharmacies conduct their business.
Despite concerns about increased transmissibility, experts are optimistic that the current vaccines will provide some level of protection when combined with the body's immune response.
